EVOTEC SE ADR 1/2 O.N. - Asset Resilience Ratio
EVOTEC SE ADR 1/2 O.N. (EVTA) has an Asset Resilience Ratio of 3.57% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See EVTA current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how EVOTEC SE ADR 1/2 O.N.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see EVTA current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down EVOTEC SE ADR 1/2 O.N.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore EVOTEC SE ADR 1/2 O.N. strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €61.23 Million | 3.57% |
| Total Liquid Assets | €61.23 Million | 3.57% |
Asset Resilience Insights
- Limited Liquidity: EVOTEC SE ADR 1/2 O.N. maintains only 3.57% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
EVOTEC SE ADR 1/2 O.N. Industry Peers by Asset Resilience Ratio
Compare EVOTEC SE ADR 1/2 O.N.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for EVOTEC SE ADR 1/2 O.N. (2021–2025)
The table below shows the annual Asset Resilience Ratio data for EVOTEC SE ADR 1/2 O.N..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.57% | €61.23 Million ≈ $71.58 Million |
€1.71 Billion ≈ $2.00 Billion |
-1.16pp |
| 2024-12-31 | 4.73% | €90.41 Million ≈ $105.70 Million |
€1.91 Billion ≈ $2.24 Billion |
+0.59pp |
| 2023-12-31 | 4.14% | €93.20 Million ≈ $108.96 Million |
€2.25 Billion ≈ $2.63 Billion |
-9.45pp |
| 2022-12-31 | 13.58% | €306.61 Million ≈ $358.46 Million |
€2.26 Billion ≈ $2.64 Billion |
+6.46pp |
| 2021-12-31 | 7.12% | €159.17 Million ≈ $186.09 Million |
€2.24 Billion ≈ $2.61 Billion |
-- |
About EVOTEC SE ADR 1/2 O.N.
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more